Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Indinavir-associated maculopapular eruption.

H B Fung1, R A Pecini, S T Brown

  • 1Division of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York 11201, USA.

Pharmacotherapy
|November 11, 1999
PubMed
Summary

Adverse skin reactions to indinavir, an HIV medication, are uncommon. A patient experienced a rash after starting indinavir, which resolved upon discontinuation and was confirmed via rechallenge.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microwave observations reveal the deep extent and structure of Jupiter's atmospheric vortices.

Science (New York, N.Y.)·2021
Same author

Associations of marijuana with markers of chronic lung disease in people living with HIV.

HIV medicine·2020
Same author

Impact of defined clinical population and missing data on temporal trends in HIV viral load estimation within a health care system.

HIV medicine·2015
Same author

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.

Journal of medical economics·2014
Same author

Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers.

HIV medicine·2009
Same author

Functional mitochondria are required for O2 but not CO2 sensing in immortalized adrenomedullary chromaffin cells.

American journal of physiology. Cell physiology·2008

Area of Science:

  • Dermatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Adverse dermatologic reactions to antiretroviral therapy can impact patient adherence and treatment outcomes.
  • Indinavir is a protease inhibitor used in combination regimens for human immunodeficiency virus (HIV) infection.

Observation:

  • A 39-year-old HIV-positive male without prior allergies developed an erythematous, maculopapular eruption shortly after initiating a triple-drug regimen including indinavir.
  • The rash resolved within two weeks of discontinuing the indinavir-containing combination therapy.

Findings:

  • Sequential rechallenge with individual antiretroviral agents confirmed indinavir as the causative agent for the adverse dermatologic reaction.
  • The patient successfully tolerated an alternative regimen of stavudine, didanosine, and nelfinavir, indicating no cross-reactivity with nelfinavir.

Related Experiment Videos

  • The rapid onset of the reaction suggests a potential immunoglobulin-E mediated hypersensitivity.

    • Implications:

    • This case highlights the importance of recognizing and managing indinavir-associated dermatologic adverse events.
    • Establishing the specific drug responsible is crucial for preserving future treatment options in HIV management.
    • Understanding potential hypersensitivity mechanisms can guide safer antiretroviral prescribing practices.